Abstract
The incidence of diabetes is increasing, but that of diabetic retinopathy is falling, probably owing to better management of glucose levels, lipid abnormalities, and hypertension. Clinical trials of VEGF and PPAR-α inhibitors are improving vision and providing insights into pathogenesis.
Citation impact
1,573
total citations
- FWCI
- 68.04
- Percentile
- 100%
- References
- 89
Citations per year
Authors
3Topics & keywords
Topics
Keywords
- Medicine
- Diabetic retinopathy
- Pathogenesis
- Incidence (geometry)
- Retinopathy
- Diabetes mellitus
- Ophthalmology
- Clinical trial
No related works found for this paper.